Literature DB >> 17449492

Expression of IL-19 correlates with Th2 cytokines in uraemic patients.

Chung-Hsi Hsing1, Chuan-Chih Hsu, Wei-Yu Chen, Lih-Yun Chang, Jyh-Chang Hwang, Ming-Shi Chang.   

Abstract

BACKGROUND: Patients with end-stage renal disease are thought to be in a chronic state of inflammation. They also have an impaired immune response with a dysregulated Th1/Th2 cytokine network. Interleukin (IL)-19, which belongs to the IL-10 family, is a newly discovered proinflammatory cytokine. IL-19 alters the balance of Th1/Th2 cells in favour of Th2. The aims of the present study were to assess the changes in serum levels of IL-19 and their correlation with Th2 cytokine production in uraemic patients.
METHODS: Seventy-three uraemic patients with haemodialysis were evaluated; 33 healthy volunteers served as controls. Serum levels of IL-19, -4, -5, -6, -10, -13 and tumour necrosis factor (TNF)-alpha were analysed using ELISA. Monocytes and T cells isolated from the patients and healthy volunteers were cultured in vitro, and cytokine production was determined.
RESULTS: IL-19 expression in the patients; but not in healthy controls, correlated positively with both the proinflammatory cytokines (IL-6 and TNF-alpha) and the Th2 cytokines (IL-4, IL-5, IL-6, IL-10 and IL-13). Cultured monocytes from patients with high IL-19 serum levels produced more IL-19 in vitro. Additionally, uraemic serum or oxidized low-density lipoproteins up-regulated the IL-19 transcripts expression in resting monocytes. Compared with T cells from healthy controls, uraemic T cells expressed more endogenous Th2 cytokine transcripts and further responded to IL-19 stimulation in Th2 cytokine production in vitro.
CONCLUSIONS: IL-19 expression in uraemic patients correlated with Th2 immune responses which might be involved in the cytokine dysregulation in uraemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449492     DOI: 10.1093/ndt/gfm179

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.

Authors:  Amy S Paller; Yael Renert-Yuval; Maria Suprun; Hitokazu Esaki; Margeaux Oliva; Thy Nhat Huynh; Benjamin Ungar; Norma Kunjravia; Rivka Friedland; Xiangyu Peng; Xiuzhong Zheng; Yeriel D Estrada; James G Krueger; Keith A Choate; Mayte Suárez-Fariñas; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2016-08-20       Impact factor: 10.793

2.  The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis.

Authors:  Matjaz Vogelsang; Carlos N Martinez; Justin Rendleman; Anuj Bapodra; Karolina Malecek; Artur Romanchuk; Esther Kazlow; Richard L Shapiro; Russell S Berman; Michelle Krogsgaard; Iman Osman; Tomas Kirchhoff
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

3.  Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: important implications in asthma.

Authors:  Fei Huang; Shinichiro Wachi; Philip Thai; Artem Loukoianov; Kin Hup Tan; Rosanna Malbran Forteza; Reen Wu
Journal:  J Allergy Clin Immunol       Date:  2008-06       Impact factor: 10.793

4.  Interleukin-4 up-regulation of epidermal interleukin-19 expression in keratinocytes involves the binding of signal transducer and activator of transcription 6 (Stat6) to the imperfect Stat6 sites.

Authors:  Lei Bao; Jaime B Alexander; Vivian Y Shi; Girish C Mohan; Lawrence S Chan
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

5.  Chemokine profile in the sera and urine of patients with schistosomal glomerulopathy.

Authors:  Alba Otoni; Antônio Lúcio Teixeira; Izabela Voieta; Carlos Maurício Antunes; Vinícius Lins Costa Melo; Sandra Costa Drummond; Valério Ladeira Rodrigues; José Roberto Lambertucci
Journal:  Am J Trop Med Hyg       Date:  2013-11-04       Impact factor: 2.345

6.  Interleukin-19: a constituent of the regulome that controls antigen presenting cells in the lungs and airway responses to microbial products.

Authors:  Carol Hoffman; Sung-Hyun Park; Eleen Daley; Claire Emson; Jennifer Louten; Maureen Sisco; Rene de Waal Malefyt; Gabriele Grunig
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

7.  Interleukin-19 impairment in active Crohn's disease patients.

Authors:  Elisabet Cantó; Esther Garcia Planella; Carlos Zamora-Atenza; Juan Camilo Nieto; Jordi Gordillo; Ma Angels Ortiz; Isidoro Metón; Elena Serrano; Esteban Vegas; Orlando García-Bosch; Cándido Juárez; Sílvia Vidal
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

8.  Detection of interleukin-19 mRNA in C57BL/6 mice astroglial cells and brain cortex.

Authors:  Bahareh Abd Nikfarjam; Massoumeh Ebtekar; Farzaneh Sabouni; Zahra Pourpak; Maryam Kheirandish
Journal:  Basic Clin Neurosci       Date:  2014

Review 9.  Interleukin-19 in breast cancer.

Authors:  Ying-Yin Chen; Chien-Feng Li; Ching-Hua Yeh; Ming-Shi Chang; Chung-Hsi Hsing
Journal:  Clin Dev Immunol       Date:  2013-04-22

10.  Inhibiting interleukin-19 activity ameliorates esophageal squamous cell carcinoma progression.

Authors:  Chung-Hsi Hsing; Franky Antonius Kwok; Hung-Chi Cheng; Chien-Feng Li; Ming-Shi Chang
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.